Trial Profile
Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Novaferon (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 25 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 03 Jun 2015 New trial record